GlassScriptPhysician profile
Lisa Marie Wallace
NPI 1134438286
$1,749.74
in general payments reported to CMS, 2019-2025
34 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $528 · 2023: $590 · 2024: $173 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.06 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $224.02 | 2021-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $199.29 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Seagen INC. | $155.95 | 2022-2023 | Tukysa |
| Genzyme Corporation | $133.70 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $114.12 | 2021-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $78.74 | 2022-2023 | Opdivo |
| Pfizer INC. | $70.12 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.20 | 2023-2024 | Jardiance |
| Astellas Pharma US INC | $65.00 | 2021 | |
| Celgene Corporation | $55.41 | 2022-2023 | Pomalyst |
| Genentech USA, INC. | $48.88 | 2022-2023 | Alecensa, Rozlytrek, Gavreto |
| Amgen INC. | $44.19 | 2023 | Lumakras, Kyprolis |
| Glaxosmithkline, LLC. | $39.98 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $32.01 | 2023-2024 | Inpefa |
| Janssen Biotech, INC. | $31.90 | 2022-2023 | Imbruvica |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $31.16 | 2025 | Stimufend |
| Abbott Laboratories | $26.62 | 2025 | Cardiomems |
| Kestra Medical Technology Services, INC. | $24.57 | 2024 | Assure Wcd |
| Alexion Pharmaceuticals, INC. | $23.87 | 2023 | Ultomiris |
| Eisai INC. | $22.39 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $22.08 | 2024 | Brilinta |
| Novartis Pharmaceuticals Corporation | $21.05 | 2023 | |
| Beone Medicines USA, INC. | $20.96 | 2025 | Brukinsa |
| Exelixis INC. | $20.78 | 2023 | Cabometyx |
| Boston Scientific Corporation | $20.25 | 2023 | |
| Pharmaessentia USA Corporation | $19.52 | 2023 | Besremi |
| Regeneron Healthcare Solutions, INC. | $19.45 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.34 | 2023 | |
| Adc Therapeutics America, INC. | $17.73 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $17.46 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.46 | 2025 | Lifevest |
| Esperion Therapeutics, INC. | $15.90 | 2024 | Nexletol |
| Ironwood Pharmaceuticals, INC | $15.40 | 2023 | Linzess |
| Merck Sharp & Dohme LLC | $15.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.